leisure time -WSS

leisure time

author：comprehensive 2025-08-28 13:07:24 - browse：32171

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Surge in Apellis stock fueled by confidence in safety of its eye drug

hotspot

WSS

Schizophrenia gene found to be linked to cells' energy dysfunction

Google's generative AI to analyze medical images — and talk to docs

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

Sage considers ways to reduce costs following FDA rejection

Tuberculosis patients need more than just free medication

Illumina slashes 2023 revenue projections yet again

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

In Memoriam: Notable people who died in 2023

Many breast cancer patients receive more radiation than needed

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Biden administration begins canceling student loan debt for 804,000 borrowers

Affirmative action in medical school literally saved lives

Biogen’s boardroom scandal saddles CEO with first crisis

Medical leaders decry Supreme Court decision on affirmative action

'Brian's Song' at 50 still offers lessons about cancer for today

ChatGPT in medicine: STAT answers readers' burning questions

Be careful with at

entertainment

Doctors are clamoring for more clarity on Paxlovid prescribing

Kansas bar where gunfire wounded 9 last month closes permanently

Mark Cuban is blaming the wrong people for high drug costs

Pennsylvania man bitten on the head by bear during attack in his garage

Biogen’s boardroom scandal saddles CEO with first crisis

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

hotspot

focus

focus

leisure time